{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:17:08Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 21.1, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09554-b939-7a03-ba64-bdb36b979cfe\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: metaraminol\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 reg", "usd": 0.0, "recall": true }, "codex": { "seconds": 76.3, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09554-b93d-79e0-8748-e64ce569e6c2\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: metaraminol\nRegistry id: vr.tr.metaraminol\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:54:52+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:30+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q409981", "registryId": "vr.tr.metaraminol", "name": "metaraminol", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q409981/", "model": { "registry_id": "vr.tr.metaraminol", "name": "metaraminol", "purpose": "Enable an agent to recognise metaraminol, assess the identity and condition of its material forms, and determine which handling or use decisions require further evidence.", "definition": "Metaraminol is a sympathomimetic amine with direct and indirect adrenergic activity, predominantly producing alpha-adrenergic vasoconstriction, that is used medicinally as a vasopressor to raise arterial blood pressure.", "scope_statement": "This model owns vr.tr.metaraminol in PHY / PHY.MAT: the stereochemically defined active substance, its material quality and state, and its relationships to salts and medicinal products.", "in_scope": [ "Molecular identity, stereochemistry and substance identifiers", "Free-base identity and relationships to specified salt forms", "Assay, stereochemical purity, impurities and material grade", "Physical properties, stability and storage conditions tied to material form", "Substance-level pharmacological activity, hazards and regulatory identity" ], "out_of_scope": [ "Finished medicinal product formulations, packaging and marketing authorisations", "Patient-specific prescribing, dosing and administration decisions", "Hypotension diagnosis and treatment pathways", "Manufacturing processes and production equipment", "Independent models of counterions, excipients and alternative vasopressors" ], "distinguishing_features": [ "Match the structure to 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol; the molecular formula alone cannot establish stereochemical identity. [FDA substance record](https://precision.fda.gov/uniisearch/srs/unii/818u2pz2eh)", "Check the meta phenolic hydroxyl, side-chain hydroxyl, primary amine and methyl substitution together when distinguishing related phenylethanolamines. [PubChem metaraminol](https://pubchem.ncbi.nlm.nih.gov/compound/Metaraminol)", "Distinguish the parent substance from metaraminol bitartrate by counterion and composition; they have separate compound records. [PubChem bitartrate record](https://pubchem.ncbi.nlm.nih.gov/compound/Metaraminol-Bitartrate)", "Check whether a stated mass refers to metaraminol equivalent or the salt: a medicinal product may express strength as metaraminol while containing the tartrate. [Product composition](https://www.medicines.org.uk/emc/product/14774/smpc)" ], "characteristics": [ { "name": "Stereochemical identity", "kind": "category", "unit_or_values": "Structure and absolute configuration; confirmed, conflicting or unverified", "why_it_matters": "A related stereoisomer must not inherit metaraminol identity solely through a shared formula or name." }, { "name": "Material form", "kind": "category", "unit_or_values": "Free base, identified salt or solution containing a specified form; hydration and solvation stated", "why_it_matters": "Composition, formula mass and physical properties depend on the actual form." }, { "name": "Substance identifier mapping", "kind": "relation", "unit_or_values": "CAS, PubChem CID, EC and UNII records with authority, form and verification date", "why_it_matters": "Identifier reconciliation prevents parent-substance and salt records from being merged incorrectly." }, { "name": "Assay and reporting basis", "kind": "measurement", "unit_or_values": "% w/w or mg/g; as-is, dried or anhydrous basis; salt mass or metaraminol equivalent", "why_it_matters": "An assay value is interpretable only when its denominator and chemical basis are explicit." }, { "name": "Stereochemical and related-substance purity", "kind": "measurement", "unit_or_values": "Specified stereoisomers and impurities in %, ppm or mg/g, with analytical method", "why_it_matters": "Total assay can conceal stereochemical contamination or degradation." }, { "name": "Solution concentration", "kind": "measurement", "unit_or_values": "mg/mL metaraminol equivalent or mmol/L of an explicitly identified species", "why_it_matters": "Concentration comparisons and conversions require a consistent substance basis." }, { "name": "Physical-property evidence", "kind": "measurement", "unit_or_values": "Melting or decomposition temperature in °C; solubility in g/L; pKa; pressure, solvent, pH and method as applicable", "why_it_matters": "Properties measured for one salt or formulation cannot automatically describe another form." }, { "name": "Material disposition", "kind": "state", "unit_or_values": "Awaiting testing, released for specified purpose, quarantined, rejected or expired", "why_it_matters": "Recognition as metaraminol does not establish suitability for a proposed use." }, { "name": "Hazard and regulatory applicability", "kind": "relation", "unit_or_values": "Form-specific SDS, jurisdictional classification, exposure-limit source and applicable quality standard", "why_it_matters": "Handling requirements and regulatory claims need a traceable scope." } ], "affordances": [ "Reconcile a named sample with the correct parent-substance or salt identity.", "Compare analytical results against a specified metaraminol material standard.", "Convert salt quantities to metaraminol equivalents when stoichiometry, hydration and assay are verified.", "Identify missing stability or compatibility evidence before proposing material handling.", "Flag identity conflicts, degradation evidence or unsupported grade claims for review.", "Link substance evidence to a medicinal product or clinical model without inferring a patient treatment." ], "agent_conduct": { "may": [ "Identify metaraminol as a vasopressor used in hospital care, citing sources.", "Report stock, expiry and storage of a held supply to the responsible pharmacy." ], "must_not": [ "Recommend a dose or use of metaraminol for a person.", "Suggest using it outside a monitored clinical setting.", "Supply or describe ways to obtain it outside lawful channels.", "Use expired, unlabelled or wrongly diluted products." ], "requires_human": [ "Any decision to give it to a patient.", "Disposing of stock of the medicine." ] }, "ethics": { "considerations": [ "It raises blood pressure sharply, so wrong use can cause serious harm.", "Patients receiving it are often critically ill and unable to consent." ], "affected_parties": [ "Patients", "Clinicians and pharmacists", "Laboratory staff" ] }, "owners": { "steward": "The hospital pharmacy or manufacturer holding it; the medicines regulator authorizes its use.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "As a medicine, clear injectable solutions in labelled ampoules or vials.", "The label states the active substance and strength; it cannot be identified by sight." ], "failure_modes_and_hazards": [ "Dosing and dilution errors in clinical use.", "Confusion with other vasopressors stocked nearby." ], "standards_and_regulation": [ "Globally Harmonized System of Classification and Labelling of Chemicals (GHS), United Nations." ], "what_it_is_for": [ "Metaraminol is encountered in hospital care as a vasopressor used to raise arterial blood pressure in selected hypotensive states.", "It is also encountered in pharmaceutical manufacture, quality control and analytical testing of medicinal preparations." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q409981: metaraminol", "url": "https://www.wikidata.org/wiki/Q409981", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Metaraminol", "url": "https://en.wikipedia.org/wiki/Metaraminol", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "molecular-identity-and-form", "name": "Molecular identity and form", "description": "Establish which chemical entity a metaraminol record or sample represents.", "rationale": "Shared names can obscure differences between stereoisomers, the parent substance and salts.", "layers": [ { "id": "structure-and-stereochemistry", "name": "Structure and stereochemistry", "description": "Resolve molecular connectivity and absolute configuration.", "findings": [ { "id": "identity-evidence", "name": "Identity evidence", "description": "Require structure-sensitive evidence for identifying a sample as metaraminol.", "questions": [ { "text": "What structural and stereochemical definition anchors this record to metaraminol?", "kind": "definition", "id": "identity-evidence-q01" }, { "text": "Which reference standard and analytical methods distinguish metaraminol from positional and stereochemical alternatives?", "kind": "measurement", "id": "identity-evidence-q02" } ] } ] }, { "id": "parent-and-salt-records", "name": "Parent and salt records", "description": "Relate material forms without treating them as interchangeable identities.", "findings": [ { "id": "form-specific-identifiers", "name": "Form-specific identifiers", "description": "Attach identifiers and names to their precise chemical scope.", "questions": [ { "text": "Does each CAS, PubChem, EC or UNII identifier denote the parent substance, a particular salt or a broader stereochemical record?", "kind": "boundary", "id": "form-specific-identifiers-q01" }, { "text": "What evidence establishes the counterion, stoichiometry and hydration state of material described as metaraminol tartrate or bitartrate?", "kind": "provenance", "id": "form-specific-identifiers-q02" } ] } ] } ] }, { "id": "composition-and-quality", "name": "Composition and quality", "description": "Assess metaraminol content, contaminants and fitness for a declared material purpose.", "rationale": "A correct substance name does not establish assay accuracy, stereochemical purity or pharmaceutical suitability.", "layers": [ { "id": "assay-and-equivalence", "name": "Assay and equivalence", "description": "Make metaraminol quantity comparable across bases and forms.", "findings": [ { "id": "quantity-basis", "name": "Quantity basis", "description": "Keep measured content separate from assumptions about salt-to-parent conversion.", "questions": [ { "text": "Is the assay or concentration expressed as metaraminol equivalent, salt mass or another explicitly defined basis?", "kind": "measurement", "id": "quantity-basis-q01" }, { "text": "Are stoichiometry, water content and assay sufficiently established to support the proposed quantity conversion?", "kind": "action", "id": "quantity-basis-q02" } ] } ] }, { "id": "impurities-and-grade", "name": "Impurities and grade", "description": "Evaluate the impurity profile and evidence behind a grade claim.", "findings": [ { "id": "quality-acceptance", "name": "Quality acceptance", "description": "Connect metaraminol lot results to an identified specification and intended use.", "questions": [ { "text": "Which stereoisomers, related substances, residual solvents and elemental impurities are measured, and by which methods?", "kind": "measurement", "id": "quality-acceptance-q01" }, { "text": "Which specification and certificate support the claimed grade, and what proposed uses remain unsupported?", "kind": "boundary", "id": "quality-acceptance-q02" } ] } ] } ] }, { "id": "physical-state-and-stability", "name": "Physical state and stability", "description": "Record form-dependent properties and evidence that material remains within specification.", "rationale": "Metaraminol base, salts and solutions require separately scoped physical and stability evidence.", "layers": [ { "id": "conditional-properties", "name": "Conditional properties", "description": "Tie property measurements to the tested chemical form and conditions.", "findings": [ { "id": "property-applicability", "name": "Property applicability", "description": "Prevent unsupported transfer of constants between material forms.", "questions": [ { "text": "What phase, solubility, acid-base and thermal-transition measurements exist for this exact form under stated conditions?", "kind": "measurement", "id": "property-applicability-q01" }, { "text": "Does a reported melting or boiling value describe a measured transition, decomposition or a prediction?", "kind": "provenance", "id": "property-applicability-q02" } ] } ] }, { "id": "degradation-and-storage", "name": "Degradation and storage", "description": "Relate material condition to exposure history and validated stability limits.", "findings": [ { "id": "continued-fitness", "name": "Continued fitness", "description": "Require evidence before retaining or rejecting exposed metaraminol material.", "questions": [ { "text": "Which stability studies establish sensitivity to temperature, light, oxygen, moisture or solution pH for this form?", "kind": "provenance", "id": "continued-fitness-q01" }, { "text": "What analytical results and exposure records determine whether the material can remain released after a storage excursion?", "kind": "action", "id": "continued-fitness-q02" } ] } ] } ] }, { "id": "biological-activity-and-product-boundary", "name": "Biological activity and product boundary", "description": "Connect substance activity to relevant biological evidence and containing products.", "rationale": "Pharmacological activity helps explain metaraminol's use, while product composition controls many practical constraints.", "layers": [ { "id": "pharmacological-evidence", "name": "Pharmacological evidence", "description": "Scope claims about pressor activity and adrenergic mechanisms.", "findings": [ { "id": "activity-context", "name": "Activity context", "description": "Metaraminol products are indicated for certain acute hypotension settings; the model must retain the context of supporting activity claims. [Product information](https://www.medicines.org.uk/emc/product/14774/smpc)", "questions": [ { "text": "Which evidence distinguishes direct receptor effects from indirect mechanisms for metaraminol?", "kind": "provenance", "id": "activity-context-q01" }, { "text": "Under what assay, species, exposure and endpoint conditions were activity or potency measured?", "kind": "measurement", "id": "activity-context-q02" } ] } ] }, { "id": "containing-products", "name": "Containing products", "description": "Separate active-substance properties from finished formulation requirements.", "findings": [ { "id": "formulation-specific-constraints", "name": "Formulation-specific constraints", "description": "A reviewed product contains sodium metabisulfite; excipient composition belongs to its product record. [Product composition](https://www.medicines.org.uk/emc/product/14774/smpc)", "questions": [ { "text": "Which linked product records specify metaraminol form, equivalent concentration, excipients and route?", "kind": "boundary", "id": "formulation-specific-constraints-q01" }, { "text": "Which compatibility, dilution and container-contact claims are demonstrated for the exact formulation and conditions proposed?", "kind": "action", "id": "formulation-specific-constraints-q02" } ] } ] } ] }, { "id": "hazards-and-use-eligibility", "name": "Hazards and use eligibility", "description": "Determine which handling and regulatory constraints apply to identified metaraminol material.", "rationale": "Material hazards, clinical risks and product permissions require different evidence and cannot substitute for one another.", "layers": [ { "id": "exposure-and-handling", "name": "Exposure and handling", "description": "Resolve occupational and environmental handling requirements for the actual material.", "findings": [ { "id": "material-hazard-evidence", "name": "Material hazard evidence", "description": "Ground precautions in a form-specific safety assessment rather than the medicine name alone.", "questions": [ { "text": "Which current SDS and jurisdictional GHS classification apply to this form, purity and concentration?", "kind": "provenance", "id": "material-hazard-evidence-q01" }, { "text": "What documented exposure limits or control assessments support containment, spill response and disposal decisions?", "kind": "action", "id": "material-hazard-evidence-q02" } ] } ] }, { "id": "standards-and-disposition", "name": "Standards and disposition", "description": "Connect intended use to quality standards and applicable regulatory records.", "findings": [ { "id": "eligible-material-use", "name": "Eligible material use", "description": "Record the evidence needed to release a lot for a named purpose without treating substance identity as product authorisation.", "questions": [ { "text": "Which current pharmacopoeial or other recognised specifications cover the exact metaraminol form in the relevant jurisdiction?", "kind": "provenance", "id": "eligible-material-use-q01" }, { "text": "Does the lot meet the requirements for its proposed use, or must it remain quarantined pending identity, quality or regulatory review?", "kind": "action", "id": "eligible-material-use-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is a recall-based description; no sources were consulted.", "Verify stereochemical identity and separate registry identifiers for the free base and salt before assigning CAS, PubChem or EC records.", "Check authoritative product information and substance-specific safety data for approved indications, formulation strengths, physical constants and hazard classifications." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of metaraminol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Metaraminol free base", "Metaraminol tartrate, a pharmaceutical salt form" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of metaraminol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "metaraminol", "note": "Names the active substance; salt forms and finished medicinal products require further specification." }, { "scheme": "WHO Anatomical Therapeutic Chemical (ATC) classification", "value_or_pattern": "C01CA09", "note": "Classifies metaraminol among adrenergic and dopaminergic agents." }, { "scheme": "Molecular formula", "value_or_pattern": "C9H13NO2", "note": "Composition of the free base; does not uniquely specify stereochemistry or describe the tartrate salt." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of metaraminol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Treatment of acute hypotension in monitored clinical settings.", "Correction of hypotension associated with anaesthesia." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of metaraminol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of the free base", "typical_range": "167.21", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of metaraminol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Excessive vasoconstriction can cause hypertension and impair tissue perfusion.", "Extravasation of injectable preparations can cause local tissue ischaemia and necrosis.", "Reflex bradycardia and cardiac arrhythmias can occur.", "Monoamine oxidase inhibitors and other interacting medicines can intensify its pressor effects.", "Confusing salt mass with active-base equivalent, or confusing injection concentrations, can cause dosing errors." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of metaraminol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Marketing authorisations, available formulations and labelled indications differ between jurisdictions." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of metaraminol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Metaraminol tartrate", "difference": "A salt containing metaraminol and a tartrate counterion; its formula and molar mass differ from those of the free base." }, { "name": "Phenylephrine", "difference": "A distinct sympathomimetic used as a vasoconstrictor, acting principally through direct alpha-1 receptor stimulation." }, { "name": "Noradrenaline", "difference": "An endogenous catecholamine with alpha-adrenergic and beta-1 activity; metaraminol is a non-catecholamine sympathomimetic." }, { "name": "Metaraminol injection", "difference": "A finished medicinal formulation with a specified concentration and excipients, rather than the chemical substance alone." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of metaraminol this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which CAS and EC identifiers authoritatively distinguish stereochemically defined metaraminol, less-specific records and its salts?", "Which current pharmacopoeial monographs establish form-specific identity, assay and stereochemical impurity limits?", "What measured solubility, pKa and thermal data exist for the free base and relevant salts, with conditions and decomposition clearly distinguished?", "Which degradation products and exposure conditions determine bulk-material retest periods independently of finished-product shelf lives?", "What jurisdiction-specific GHS classifications and occupational exposure limits are established for the relevant material forms?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 28 } }